A recent study reveals that individuals who stop using blockbuster GLP-1 drugs like semaglutide or tirzepatide may regain shed pounds far faster than those who end conventional lifestyle plans.
Findings released in a major health publication shows that while obese individuals can lose about a fifth of their body weight while using the jabs, the weight comes back at an estimated rate of nearly a kilo each month upon discontinuation.
"Individuals purchasing such treatments must be aware of the danger of rapid weight regain when the therapy is stopped," stated lead investigator Dr. Susan Jebb.
This pace of recovery implies a return to pre-treatment mass within about a year and a half.
Analyzing Treatments
The study, which looked at 37 of studies involving over 9,000 of participants, compared the effects of the injectable medications with other pills.
The team point out that people who shed pounds through dieting typically see a more gradual weight regain—approximately 100 grams monthly—after stopping.
Explaining the Quick Rebound
Doctors suggest the mechanism of the injections is key to understanding the amplified regain.
The injections imitate a body's own chemical called glucagon-like peptide-1, which controls appetite.
"Long-term administration of the hormone levels several times higher than the body's typical production may cause the system to generate a reduced amount of its endogenous GLP-1, and may also lessen sensitivity to its actions," explained Dr. Adam Collins, a dietetics researcher.
"Discontinuation of this GLP-1 'fix' results in hunger is no longer kept in check, making overeating much more probable."
An Ongoing Issue?
Health authorities advise the jabs for individuals with weight-linked health risks, accompanied by prescribed lifestyle changes.
A number of clinicians argue that, due to the likelihood of relapse, the treatment should be considered life-long.
This opinion is supported by drug manufacturers, who say that the results "emphasize the chronic character of obesity," comparing it to managing conditions like hypertension.
User Experiences
Individuals who have come off the medication describe a sudden resurgence of hunger.
"It was like something activating and I was suddenly ravenous," said a patient.
This challenge is exacerbated if users have not developed lasting lifestyle or habit modifications during treatment.
Widespread Adoption
Recent estimates suggest that a significant number of people in the UK have tried weight-loss jabs in the last 12 months, with desire continuing to grow.
- Use is more common among females than males.
- The middle-aged age group shows the highest usage rates.
- A large proportion access the drugs through private healthcare rather than public health services.
Finally, clinicians stress that while the jabs are potent agents for shedding pounds, they are not a permanent cure and long-term success likely depends on ongoing behavioural changes.
